UKIBCS 2020 Evaluation

Question Title

* 1. How would you rate your overall conference experience

Question Title

* 2. Please rate the conference in terms of knowledge gained

Question Title

* 3. Do you think the programme was well balanced?

Question Title

* 4. Please rate the conference sessions you attended

  Excellent Very good Good Average Poor
Highlights
Keynote lecture: Philip Poortmans
Demystifying partial breast irradiation
Big data in breast cancer
Why can't we kill ER+ breast cancer?
Managing the side effects of endocrine therapy
Sponsored symposium: Exact Sciences
Sponsored symposium: Roche
Sponsored symposium: Pfizer
Keynote Lecture: Matthew Ellis
DCIS - Risk estimates and management
Special issues in managing metastatic disease
Phenotypic and genotypic heterogenity
Free Communications 1
Managing the axilla
Late recurrence in ER+ disease
Improving breast cancer outcomes by modifying lifestyle
Novel clinical trial design
Keynote Lecture: Eric Winer
Keynote Lecture: Martine Piccart
Modernising breast MDT meetings
Immune therapy
Modelling breast cancer - moving closer to the clinic
Trials in progress
Keynote Lecture: Judy Garber
Breast cancer risk and prevention
Prognostic and predictive profiling
Special issues in managing young patients
Free Communications II
Sponsored symposium: Nanostring
Sponsored symposium: Lilly
Sponsored symposium: Daiichi Sankyo
Keynote Lecture: Monica Morrow
Minimising mastectomy
Special issues for elderly patients
Translating new therapeutic opportunities
Young clinical leaders
Keynote Lecture: David Cameron

Question Title

* 5. How would you rate your experience of the poster viewing?

Question Title

* 6. Do you think it is useful for patient advocates to attend and participate in the UKIBCS?

Question Title

* 7. Please rate these specific aspects of the conference

  Excellent Very good Good Average Poor
Venue
Location/Access
Catering
Accommodation

Question Title

* 8. What topics would you like to suggest for future meetings?

Question Title

* 9. Do you have any other comments on the meeting?

0 of 9 answered
 

T